Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Michel Farnier Articles

PCSK9 Clinical trials: What’s new?

PCSK9 Clinical trials: What’s new?

Dr Michel Farnier MD PhD Clinician based at Point Medical, Dijon, France

read more »
ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing

ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing

Results from the ODYSSEY CHOICE studies indicate flexibility in dosing with alirocumab, with  4-weekly  regimens shown to be effective and well tolerated, according to Dr Michel Farnier, Point Medical, Dijon, France. Many patients at moderate to high cardiovascular (CV) risk and with poorly controlled hypercholesterolaemia…

read more »
PlayODYSSEY FHI FHII

ODYSSEY FHI FHII

Fewer than 80% of familial hypercholesterolaemia (FH) patients achieved an LDL-C level of

read more »
PCSK9: From discovery to therapeutic applications

PCSK9: From discovery to therapeutic applications

PUBMED abstract: http://www.ncbi.nlm.nih.gov/pubmed/24373748

read more »